Lanadelumab (KLKB1) - Research Grade Biosimilar
Product Specifications
Background
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials.Lanadelumab was developed by Shire and FDA approved on August 28, 2018.5.
Immunogen
Homo sapiens / KLKB1 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Neuroscience
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-771
Fragment
IgG1-kappa
NCBI Organism
Homo sapiens
Other Product Names
X124-G01, DX-2930
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
